REMYX
Price
$16.04
Change
+$0.03 (+0.19%)
Updated
Dec 20 closing price
RNWFX
Price
$77.72
Change
+$0.12 (+0.15%)
Updated
Dec 20 closing price
Ad is loading...

REMYX vs RNWFX

Header iconREMYX vs RNWFX Comparison
Open Charts REMYX vs RNWFXBanner chart's image
Russell Inv Emerging Markets Y
Price$16.04
Change+$0.03 (+0.19%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$77.72
Change+$0.12 (+0.15%)
VolumeN/A
CapitalizationN/A
REMYX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
REMYX vs. RNWFX commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REMYX is a Hold and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.2B vs. REMYX (716M). REMYX pays higher dividends than RNWFX: REMYX (2.52) vs RNWFX (1.51). REMYX was incepted earlier than RNWFX: REMYX (16 years) vs RNWFX (23 years). REMYX is a more actively managed with annual turnover of: 95.00 vs. RNWFX (32.00). RNWFX has a lower initial minimum investment than REMYX: RNWFX (250) vs REMYX (10000000). REMYX annual gain was more profitable for investors over the last year : 11.24 vs. RNWFX (5.86). RNWFX return over 5 years is better than : 14.39 vs. REMYX (-11.18).
REMYXRNWFXREMYX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years23 years-
Gain YTD9.0994.549200%
Front LoadN/AN/A-
Min. Initial Investment100000002504,000,000%
Min. Initial Investment IRAN/AN/A-
Net Assets716M62.2B1%
Annual Yield % from dividends2.521.51167%
Returns for 1 year11.245.86192%
Returns for 3 years-8.59-5.10168%
Returns for 5 years-11.1814.39-78%
Returns for 10 years4.4642.6710%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTRS12.520.39
+3.22%
Viatris
TEO11.890.14
+1.19%
Telecom Argentina SA
DX12.570.14
+1.13%
Dynex Capital
INTT7.680.04
+0.52%
inTEST Corp
VIRX0.21N/A
-1.87%
Viracta Therapeutics